Mavacamten should be taken once daily with or without meals at about the same time each day
Mavacamten is a once daily oral capsule1
Mavacamten is available in four dose strengths: 2.5 mg, 5 mg, 10 mg, and 15 mg
The capsule should be swallowed whole with water
Mavacamten initiation considerations1
Before treatment initiation, patients’ LVEF should be assessed by echocardiography.
If LVEF is <55%, mavacamten should not be initiated
Before initiation of mavacamten, women of childbearing potential must be informed of the risk to the foetus, have a negative pregnancy test confirmed, and must use effective contraception during treatment and for 6 months after treatment discontinuation
Patients should be genotyped for CYP2C19 in order to determine appropriate mavacamten dose. Patients with CYP2C19 poor metaboliser phenotype may have increased mavacamten exposures (up to 3 times) that can lead to increased risk of systolic dysfunction compared to normal metabolisers. If treatment initiation occurs prior to determination of CYP2C19 phenotype, patients should follow dosing instructions for poor metabolisers until CYP2C19 phenotype is determined
Mavacamten initiation in CYP2C19 intermediate, normal, rapid and ultra-rapid metaboliser phenotypes1
*Interrupt treatment if LVEF is <50% at any clinical visit; restart treatment after 4 weeks if LVEF ≥50%.1
Mavacamten initiation in CYP2C19 poor metaboliser phenotype1
*Interrupt treatment if LVEF is <50% at any clinical visit; restart treatment after 4 weeks if LVEF ≥50%.1
LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract.
Reference
- Mavacamten Summary of Product Characteristics.
3500-GB-2600066 | March 2026